Shots:

• The head-to-head P-III JADE DARE study involves assessing the efficacy of Abrocitinib (200mg- qd- PO) vs dupilumab (300mg- SC- q2w followed by 600mg induction dose) in adult patients on background topical therapy with moderate to severe AD
• The study met its co-1EPs of at least a 4-point improvement in the severity of PP-NRS4 @2wks. and the proportion of patients achieving EASI-90 @4wks. The study also met its 2EPs i.e proportion of patients achieving EASI-90 @16wks.
• In general- abrocitinib was superior to dupilumab in each evaluated efficacy measure and had a safety profile consistent with previous studies

  | Ref: Pfizer | Image: Wall Street Journal